Intarcia Therapeutics

Quote
anonymous said:
This is about the future of delivery systems for chronic diseases. Diabetes being the first of many disease states that can be looked at for new long term delivery systems. Lifelong, crippling diseases that allow for steady state consistent blood levels will lead to better outcomes. As nonotechnology continues to develop cures may not be at hand but long term treatments will provide better outcomes, improved quality of life, and cost less healthcare dollars over time. Quit thinking about what can't happen and think about the future with new and improved delivery systems. If not this one, then the next generation. At least Intarcia is moving toward the future not staying locked in the past with an X-R tablet or long acting injectable decanoate.
Happy Independence Day to all Americans!
Click to expand...

LOL - insider PR pimping? Yep like the glassdoor dot con's positive reviews, huh?
 






Damian Feuerstein said:
Is it possible to tell people that re-launching a generic is actually making it into a "new drug" ?

Bydureon/Byetta GLP-1 class volumes grew by 25% during the quarter and continues to be the fastest-growing class for patients with type-2 diabetes. Combined sales for Bydureon/Byetta were $197m, with Bydureon sales, up 11%, representing approximately 69% of total Bydureon/Byetta sales. Byetta sales declined by 30% to $62m with the Company’s focus switching to Bydureon. In the US, Bydureon sales were $108m, an increase of 2% despite increased competition from new market entrants. Sales in Europe were $23m

Who will pop the hype bubble ?
Click to expand...

It's race to the bottom for the GLP-1 drug market place in rather crowded arena with those who discount their drug the most may win the fleeting market share.

Payers MAY authorize the pricey GLP-1 implant and surgical procedure IF it is approved for those who cannot swallow pills or afraid of needles or something with no doubt big co-pay. Tiny costly niche at best...
 






anonymous said:
This is about the future of delivery systems for chronic diseases. Diabetes being the first of many disease states that can be looked at for new long term delivery systems. Lifelong, crippling diseases that allow for steady state consistent blood levels will lead to better outcomes. As nonotechnology continues to develop cures may not be at hand but long term treatments will provide better outcomes, improved quality of life, and cost less healthcare dollars over time. Quit thinking about what can't happen and think about the future with new and improved delivery systems. If not this one, then the next generation. At least Intarcia is moving toward the future not staying locked in the past with an X-R tablet or long acting injectable decanoate.
Happy Independence Day to all Americans!
Click to expand...

LOL - insider I presume? Alas if you can convince the payers, patients and endocrinologists...
 






Dead unicorn in making with bogus claim of largest private biotech. Heard they have been around for over 20 yrs and never launched a product. Any news on these guys raising yet another round of $?

As for those interested in joining the ranks of dying unicorn - question their speels beyond fantasy gobbledygook and ask yourself what will you do when they flame out of the gate and find yourself on the ranks of unemployed line.
 






anonymous said:
patents should be expiring over the next 2-3 years
Click to expand...

Best case scenario is approval by Q4 and worst case scenario is CRL (complete response letter) which will push out the approval to 6 to 24 months (if new trial is required). Oh wait patent expires bout same time.

Do I hear that giant sucking sound of cash being flushed down the toilet and down rounds around the corner?
 






Whoooooa Come Halloweeeeeen Spoooooky Exenatide Generics take over..........
  • Teva has reached an agreement with AstraZeneca allowing it to market a generic copy of the injectable diabetes drug Byetta by late next year, the Israeli drugmaker said Thursday.
  • Under the deal, Teva will be able to commercialize Byetta in the U.S. starting on October 15, 2017, although a statement alluded to certain circumstances by which sales could begin earlier.
  • While a generic competitor will crimp sales, AstraZeneca has already switched its focus to the extended release version of the GLP-1 drug, called Bydureon.
 






anonymous said:
Whoooooa Come Halloweeeeeen Spoooooky Exenatide Generics take over..........
  • Teva has reached an agreement with AstraZeneca allowing it to market a generic copy of the injectable diabetes drug Byetta by late next year, the Israeli drugmaker said Thursday.
  • Under the deal, Teva will be able to commercialize Byetta in the U.S. starting on October 15, 2017, although a statement alluded to certain circumstances by which sales could begin earlier.
  • While a generic competitor will crimp sales, AstraZeneca has already switched its focus to the extended release version of the GLP-1 drug, called Bydureon.
Click to expand...

Great news for the patients even if twice daily administration. Expect pricing pressures on the other weekly and especially daily stalwart Victoza. Yep indeed race to the bottom with the payers rule the roost.

And Intarcia boys in Boston think they are going to rule from the roost with rip-off price implant pump.
 












anonymous said:
It's amazing how recruiters have no clue about salary, bonus, company car or car allowance, sign on bonus etc. absolutely nothing. Wtf???!
Click to expand...

The word on the street is unofficial hiring freeze until they raise more money. It dawned upon these arrogant pricks that it takes shit load of money to build up the organization. They are just collecting and ranking resumes by each region by clueless temp recruiters. Also heard uncertainty is becoming more obvious at the penthouse HQ.
 










































Children, our leadership is the strongest ever assembled to tackle a major challenge to humanity in the history of the world. No doubt you felt small in our presence. We are beyond good, beyond fantastic, we are the ultimate. Rome had Emperors, France had Napolepon, Intarcia has Graves
 












anonymous said:
My experience as well interviewing..very condescending, better than you attitude...in my experience that leads to a disasterous launch.
Click to expand...

Did you have telephone interview or visit to the Boston HQ? Yep they are real arrogant pricks all right when I approached them at ADA conference. Those fuckers will be humbled sooner than later.
 












Yeah at ADA was very hard to have a reasonable conversation about Bydureon or Bayetta - keep insisting that uptake would be faster than any other drug in diabetes because pumps cure compliance
 






Top Bottom
Back
Quote